Press Releases

	Jerusalem, Israel, July 1, 2009 Teva Announces Approval and Launch of Tri-Lo Sprintec Tablets
	Jerusalem, Israel and Ewing, New Jersey, June 30, 2009 Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin® (Human Growth Hormone)
	Jerusalem, Israel, June 18, 2009 Court Grants Teva Summary Judgment Of Non-Infringement On Eloxatin®
	Jerusalem, Israel, June 9, 2009 Teva to Present at the Goldman Sachs 30th Annual Global Healthcare Conference
	Jerusalem, Israel, May 25, 2009 Teva to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fifth Annual Strategic Decision Conference 2009
	Jerusalem, Israel, May 14, 2009 Federal Circuit Affirms Denial of Preliminary Injunction Regarding Teva's Generic Protonix® Tablets
	Jerusalem, Israel and Basel, Switzerland, May 14, 2009 Lonza and Teva Announce Receipt of Regulatory Approval
	Jerusalem, Israel, May 14, 2009 Teva Announces Approval And Launch Of Generic Urso 250® And Urso Forte®
	Jerusalem, Israel, May 13, 2009 Teva Provides Update On Generic Actonel® Litigation
	Jerusalem, Israel, May 13, 2009 Teva Announces Presentations At Bank Conferences
	Jerusalem, Israel, May 6, 2009 Teva Announces Extension of Patent Protection for Azilect®
	Jerusalem, Israel, May 5, 2009 Teva reports First Quarter 2009 Results
	Jerusalem, Israel, Lund, Sweden and Seattle, Washington, April 28, 2009 New Data Illustrate Novel Mechanism of Action of Laquinimod, An Oral Compound For The Treatment of Multiple Sclerosis
	Jerusalem, Israel, April 28, 2009 Long-Term Study with COPAXONE® Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
	Jerusalem, Israel, April 23, 2009 Teva Comments on Generic Evista® Preliminary Injunction
	Jerusalem, Israel, April 22, 2009 Teva to Present New Data on its Innovative Therapies for Multiple Sclerosis and Parkinson's Disease at the Upcoming 2009 American Academy of Neurology Annual Meeting
	Jerusalem, Israel, April 20, 2009 Teva to Report First Quarter 2009 Financial Results on May 5, 2009
	Jerusalem, Israel, April 2, 2009 Teva Introduces First Generic Adderall XR® Capsules in the United States
	Jerusalem, Israel, April 1, 2009 Teva Announces Approval of Generic Yaz® Tablets
	Jerusalem, Israel, March 27, 2009 Teva Announces Approval and Launch of Generic Topamax® Tablets
	Jerusalem, Israel, March 25, 2009 Teva Announces FDA Response to Citizen Petition
	Jerusalem, Israel and Scottsdale, Arizona, March 19, 2009 Teva and Medicis Announce Settlement Agreement
	Jerusalem, Israel, March 18, 2009 Teva Announces Approval and Launch of Generic Solodyn® Extended-Release Tablets
	Jerusalem, Israel, March 17, 2009 Study Demonstrates that Qvar® is More Likely to Achieve Successful Asthma Control with Less Exacerbations
	Jerusalem, Israel, March 16, 2009 Teva to Present at the Cowen and Company 29th Annual Healthcare Conference
	Jerusalem, Israel, March 11, 2009 Teva to Present at the Barclays Capital Global Healthcare Conference
	Jerusalem, Israel, March 3, 2009 Copaxone® Approved by the FDA for Patients with a First Clinical Event Suggestive of Multiple Sclerosis
	Jerusalem, Israel, February 17, 2009 Teva Provides 2009 Financial Outlook
	Jerusalem, Israel, February 17, 2009 Teva Reports Record Full Year 2008 and Fourth Quarter Results
	Jerusalem, Israel and Lund, Sweden, February 12, 2009 Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
	Jerusalem, Israel, February 11, 2009 Teva Announces Approval and Launch of Generic Imitrex® Tablets
	Jerusalem, Israel, February 4, 2009 Copaxone® is Approved for Treatment of Patients with a First Clinical Event Suggestive of Multiple Sclerosis
	Jerusalem, Israel, January 30, 2009 Teva Announces Approval of Generic Risperdal ® Oral Solution
	Jerusalem, Israel, January 27, 2009 Teva to Report Fourth Quarter and Full Year 2008 Financial Results on February 17, 2009
	Jerusalem, Israel, and Basel, Switzerland, January 20, 2009 Teva and Lonza Announce Strategic Partnership to Become a Leading Global Provider of Biosimilars
	Jerusalem, Israel, January 8, 2009 Teva to Present at the 27th Annual J.P. Morgan Healthcare Conference
	Jerusalem, Israel, January 7, 2009 Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
	Jerusalem, Israel, January 5, 2009 Teva Announces Amir Elstein Joins Board of Directors